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The isolation, identification and total synthesis of two plant-
derived inhibitors of the NF-κB signaling pathway from the
iso-seco-tanapartholide family of natural products is de-
scribed. A key step in the efficient reaction sequence is a
late-stage oxidative cleavage reaction that was carried out in
the absence of protecting groups to give the natural products
Introduction
The search continues for bioactive compounds that can
act as leads for drug discovery or as tools for biological
studies. Whilst the use of large chemical libraries is of im-
portance in this research area,[1] approaches based on natu-
ral products remain powerful.[2] Here we describe the total
synthesis of plant-derived inhibitors of the NF-κB signaling
pathway. This pathway plays a key role in inflammation,
immunology and cancer. Compounds that modulate its ac-
tivity have been linked to the treatment of several diseases.[3]
In the initial phase, bioactive plant-derived natural-prod-
uct extracts were identified by using an NF-κB-based re-
porter-gene assay.[4] Bioactivity-guided fractionation of one
of the extracts resulted in the isolation of what was believed
to be the relevant components. Spectroscopic analysis led
to structural assignment of the compounds as members of
a natural-product family that includes the seco-[5] and iso-
seco-tanapartholides (Figure 1).[6] These interesting struc-
tures are believed to be biosynthesised by a Diels–Alder
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directly. A detailed comparison of the synthetic material with
samples of the natural products proved informative. Bio-
logical studies on synthetic material confirmed that these
compounds act late in the NF-κB signaling pathway.
(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim,
Germany, 2009)
reaction of sesquiterpene lactone derived dienes with oxy-
gen followed by fragmentation of the resulting cyclic perox-
ides to form the seco or iso-seco structures.[5,7]
Figure 1. Members of the iso-seco-tanapartholide family of natural
products isolated from plants of the genus Artemisia and Achillea.
The total synthesis of members of this natural-product
family was then carried out to confirm their structure and
biological activity. A key step in our short and efficient se-
quence was a late-stage oxidative cleavage reaction that was
carried out in the absence of protecting groups to give the
natural products directly. A comparison of the previously
reported spectroscopic data associated with the natural
products proved interesting.
This study was completed by showing that the synthetic
samples of the iso-seco-tanapartholides are indeed inhibi-
tors of the NF-κB signaling pathway. We also present ex-
periments that have enabled us to propose a mode of action
for these inhibitors.
Results and Discussion
High-throughput screening of plant-derived extracts was
carried out by using an HeLa57A cell line that expresses an
NF-κB-dependent reporter.[4,8] Failure to trigger this re-
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Figure 2. Sections of the 1H NMR spectrum of (a) the bioactive sample purified from extracts of the plant Tanacetum parthenium; signals
corresponding to two compounds are visible for the C3 proton and one each of the C2 and C13 protons; (b) synthetic sample of 1
(dotted line) and (c) synthetic sample of 2 (full line) corresponding to the major compound present in the sample from Tanacetum
parthenium.
porter on addition of phorbol 12-myristate 13-acetate indi-
cated that the tested extract inhibited the NF-κB signaling
pathway. Whilst several extracts were active, follow-up stud-
ies focused on an extract from the plant Tanacetum parthen-
ium.[9] This extract was selected due to the robust nature of
the bioactivity observed despite concerns that natural prod-
ucts with the same biological activity have been isolated
previously from this plant, including the much studied par-
thenolide.[10] Three rounds of bioactivity-guided fraction-
ation resulted in the isolation of an enriched fraction that
retained the desired activity.[8] Detailed spectroscopic analy-
sis of this fraction[8] led to its assignment as the natural
product, iso-seco-tanapartholide (reported structure 1,[6a,6b]
Figure 1), and our plans then focused on how an authentic
sample of 1 might be prepared. However, in contrast to
previous reports, our analysis showed that the sample of 1
we had isolated was in fact a mixture of two compounds.
Figure 2a shows the observed signals assigned to the C3
proton and one each of the C2 and C13 protons and clearly
shows that two signals are present for each proton. The two
compounds present in the purified extract from Tanacetum
parthenium were tentatively assigned the epimeric structures
1 and 2 (Figure 1).
Spectroscopic methods alone could not be used to assign
the stereochemistry at C3 in the two proposed structures.
The remote nature of the C3 stereocenter and the flexibility
inherent in this structure contribute to the analysis chal-
lenges, as does the fact that it was not possible in our hands
to obtain pure samples of the two epimers at this stage.
This raised additional concerns about the existing structural
assignments within the iso-seco-tanapartholide family and
provided a further motivation for preparing authentic sam-
ples of both 1 and 2.
Retrosynthetically, we envisaged accessing the seco struc-
ture in 1 by oxidative cleavage of the C1,C10 syn-diol func-
tionality in 7 in the absence of protection of the C3 alcohol
and αβ-unsaturated lactone functional groups (Figure 3).
We reasoned that if the oxidative cleavage reaction was car-
www.eurjoc.org © 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Eur. J. Org. Chem. 2009, 5711–57155712
ried out at an earlier stage in the synthesis, a considerable
increase in the total number of steps would be required. It
was therefore planned that the syn-diol unit in 7 would be
introduced by dihydroxylation of the γ,δ-double bond in
8. This dihydroxylation was expected to proceed with high
selectivity for the β-face of 8 providing the β-syn-diol 9
(Figure 3). This assumption was based on other work from
our laboratory in which epoxidation of 8 with m-CPBA fur-
nished almost exclusively the β-epoxide.[8] With β-syn-diol
9 in hand it was expected that diastereoselective reduction
of the C3 ketone and installation of the C11–C13 exo-meth-
ylene group would lead to substrates suitable for oxidative
cleavage studies.
Figure 3. Retrosynthetic analysis of iso-seco-tanapartholide.
Our initial plan involved the use of 9 directly in the C3
carbonyl reduction reaction (Scheme 1).[11] However, for
practical reasons, we were forced to revise this by carrying
out the reduction on a protected version of 9, the β-syn-
diol 10. Reduction of the C3 carbonyl group in 10 was ex-
pected to occur under steric control with approach of the
reducing agent occurring from the opposite face to the two
protected alcohols giving 7 after removal of the silyl groups.
Iso-seco-tanapartholides
As pure samples of both 1 and 2 were required, it was pro-
posed that epimerisation at C3 by using Mitsonobu proto-
cols would be possible late in the synthesis; however, this
proved unnecessary. It was planned to access the 5,7,5 guai-
anolide system in 8 by photochemical rearrangement of the
eudesmanolide (–)-α-santonin 11 to give 12 (Figure 3).[12]
The overall plan, if successful, would provide rapid access
to authentic samples of both 1 and 2.
Scheme 1. Dihydroxylation and reduction of the C3 carbonyl
group.
In practice, acid-mediated elimination of acetic acid from
12,[13] obtained from 11,[12] provided 8 in accordance with
literature precedent. Subsequent dihydroxylation of 8 gave
syn-diol 9 as the major component in a 3:1 mixture with
13, with the reaction occurring exclusively at the γ,δ-double
bond in 8. For ease of handling, the diol functionality in
both 9 and 13 was protected before reduction of the C3
carbonyl group. Attempts to protect the diol unit in 9 and
13 as acetonides proved unsuccessful returning only the
starting materials. This lack of reactivity could be rational-
ised when the X-ray structures of subsequent intermediates
were obtained.[14] In the cases of 15–17, the seven-mem-
bered ring adopts conformations in which the hydroxy
groups are positioned such that the O1–C1–C10–O10 tor-
sional angles are 45°, 74° and 55°, respectively. The rela-
tively rigid nature of this framework presumably stops the
oxygen atoms moving from their ground state positions to
adopt the required conformation for successful aceton-
isation. However, protection of 9 and 13 was achieved by
treatment with TMSOTf yielding a 3:1 mixture of bis(TMS)
ethers 10 and 14. Reaction of 10 and 14 with sodium
borohydride provided two major isomers 15 and 16 that,
despite being difficult to separate from each other, were
readily separable from minor quantities of the other two
possible isomers 17 and 18 (ratio 15+16/17+18 = 85:15;
95% yield). When this purification was repeated on a larger
scale, pure samples of 15, 16 and 17 were isolated and their
structures assigned by X-ray analysis. Alcohol 15, the major
product from the reduction of 10, and likewise alcohol 16,
the major product from the reduction of 14, result from
hydride addition to the less hindered face of the respective
ketones, as expected. As 15 and 16 could not be separated
easily, reaction of the mixture with TBSOTf resulted in tri-
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silyl ethers 19 and 20 that were readily separable. The pure
diastereoisomers 19 and 20 were then carried through the
subsequent steps independently.
The next challenge was to introduce the exocyclic α-
methylene group. Reaction of the lithium enolate generated
from 19 with diphenyl diselenide gave exclusively 21
(Scheme 2A).[15] The stereochemical outcome of this reac-
tion results from pseudoaxial approach of the electrophile
and was confirmed by nOe studies on 21.[8] Oxidation of
the selenide in 21 with concomitant elimination gave 22 as
the only product due to the anti relationship between the
C11 selenoxide and the C7 proton preventing formation of
the C7–C11 double bond (Scheme 2A). Global desilylation
by using TBAF gave triol 7 in excellent yield, and – pleas-
ingly – 7 was then converted into 1 in 86% yield on treat-
ment with lead tetraacetate at 0 °C in dichloromethane.
Interestingly, attempts to carry out this transformation by
using sodium periodate returned only starting material,
probably due to the fact that again the O1–C1–C10–O10
torsional angle in 7 is too large and inflexible to enable
formation of the required cyclic periodate ester. Whilst lead
tetraacetate is known to cleave diols that cannot form the
corresponding cyclic ester intermediate, the rates of these
reactions are extremely slow.[16] Therefore, as cleavage of 7
is complete within just 20 min, this reaction probably oc-
curs via the cyclic intermediate that can be formed in this
Scheme 2. Installation of the exocyclic double bond, global depro-
tection and oxidative cleavage.
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case due to the larger size of lead compared to iodine.[16]
When the reaction of 7 with lead tetraacetate was run for
extended times or at higher temperatures over-oxidation of
1 was observed.[17]
In an analogous sequence of reactions, the trisilyl-pro-
tected triol 20 (Scheme 1) was transformed via the selenide
23[8] into 24, a compound that contained the required exo-
cyclic α-methylene group (Scheme 2B). Subsequent de-
silylation of 24 gave 25 which, in an analogous manner to
the conversion of 7 into 1, underwent rapid and clean oxi-
dative cleavage to yield 2 (72% over 4 steps). Comparison
of the 1H and 13C NMR spectra of synthetic 1 and 2 with
that reported for iso-seco-tanapartholide isolated from
plants of the genus Artemisia[6] proved interesting. The
spectra for both 1 and 2 correlated very closely with those
reported for the natural product. In the absence of authen-
tic material from these sources, further insight was gained
by comparing the optical rotation of the natural material[6]
with those of synthetic 1 and 2.[18] Despite the small values
involved, it appears that the relative and absolute stereo-
chemistry assigned to iso-seco-tanapartholide from Artemi-
sia was correct (as in 1).
However, the situation was complicated when a compari-
son of synthetic 1 and 2 with our material from T. parthen-
ium and a sample from a plant of the genus Achillea[19] was
carried out. NMR studies (Figure 2) showed that the bioac-
tive material we had isolated from T. parthenium was indeed
a mixture of the two epimers 1 and 2 with the major isomer
isolated from this plant having the same relative stereo-
chemistry as 2 [compare Figure 2a and c (full line)]. In ad-
dition, comparison of our authentic samples of 1 and 2,
with material isolated from a plant of the genus Achillea[19]
gave an analogous result, again confirming that the major
isomer present in this sample was epi-iso-seco-tanaparthol-
ide 2. Further optical rotation comparisons[8,18] also sup-
ported our conclusion that the major isomer isolated from
Achillea had the same absolute stereochemistry as 2. For a
more detailed comparison of synthetic 1 and 2 with the
previous literature reports of their isolation, see Supporting
Information.
Figure 4. Bioactivity of 1 and 2: (a) NF-κB-dependent reporter gene assay; (b) IκBα western blot analysis after TNFα activation.
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Biological analysis[4,20] of synthetic 1 and 2 confirmed
that they inhibited the TNFα activation of NF-κB [IC50(1)
= 7.70.6 μm; IC50(2) = 4.70.2 μm; Figure 4A] over a
concentration range similar to that observed for our iso-
lated material.[8] To establish the mode of inhibition, cells
were treated with the NF-κB activator TNFα and levels of
the NF-κB inhibitor IκBα determined by western blotting.
In response to TNFα, IκBα is rapidly degraded and then
resynthesized as the IκBα gene is NF-κB-dependent (Fig-
ure 4B; DMSO vector). However, in the presence of 1 and
2, IκBα was degraded, but resynthesis of IκBα was not ob-
served. This indicates that 1 and 2 do not prevent IκBα
degradation but block the transcriptional activity of NF-
κB. Immunofluorescence studies were also consistent with
this assumption.[8] In addition, we determined the effect of
1 and 2 on the DNA binding activity of NF-κB. Recombi-
nant-purified DNA-binding domains of the p50 and p65
subunits of NF-κB were incubated with 1 and 2 and a gel
electrophoresis DNA-binding assay performed.[8] Both 1
and 2 inhibited NF-κB-DNA binding in a dose-dependent
fashion only when a thiol-based reducing agent was absent
from the assay. The observed loss of biological activity of 1
and 2 in the presence of a thiol is consistent with a mode
of action for these compounds in which covalent modifica-
tion of cysteine residues in either the p50 or p65 subunit of
NF-κB occurs. In addition, a close analogue of 1 in which
the exocyclic α-methylene group was replaced by a methyl
group [C11-(S)] did not inhibit TNFα activation of NF-κB,
again suggestive of a role for the exocyclic α-methylene
group in 1 as an electrophile. Interestingly, covalent modifi-
cation of cysteine by inhibitors of NF-κB activation, includ-
ing the sesquiterpene lactones, has been proposed previous-
ly.[4b,21] In particular, a computational model of the pro-
posed covalent binding mode of the sesquiterpene lactone,
helenalin, to Cys38 and Cys120 of the p65 subunit of NF-
κB has been described.[22] Attempts to overlap the structure
of the iso-seco-tanapartholides onto this model suggest that
the C3 functional group would be expected to point away
from the protein. If correct, this would provide an explana-
tion for the observed disruption of the NF-κB-DNA inter-
Iso-seco-tanapartholides
action by both 1 and 2, in a manner that is independent of
the C3 stereochemistry.
Conclusions
The bioactivity-guided fractionation of an extract from
Tanacetum parthenium by using an NF-κB-dependent lucif-
erase reporter gene assay is described. The purified extract
was shown to contain two natural products from the iso-
seco-tanapartholide family. Synthesis of authentic samples
of these two natural products by using an efficient oxidative
cleavage reaction clarified the structures of the compounds
isolated from a series of plants. This resulted in the isolation
and synthesis of the natural product epi-iso-seco-tanapar-
tholide (2) as well as iso-seco-tanapartholide (1). Biological
studies on synthetic material confirmed that these com-
pounds act late in the NF-κB signaling pathway.
Supporting Information (see footnote on the first page of this arti-
cle): Details of the Strathclyde natural-product extract collection,
screening results, bioactivity-guided purification, structural assign-
ment, experimental procedures, characterisation data for all new
compounds, comparison studies of synthetic 1 and 2 with pre-
viously reported natural products and material isolated from T.
parthenium and Achillea.
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